Eupraxia Pharmaceuticals Statistics
Want to see TSE:EPRX full AI Analyst Report?
Eupraxia Pharmaceuticals (EPRX) Stock Statistics & Valuation Metrics
Total Valuation
Eupraxia Pharmaceuticals has a market cap or net worth of CAD 600.98M. The enterprise value is CAD 745.29M.
- Market Cap
- CAD 600.98M
- Enterprise Value
- CAD 745.29M
Share Statistics
Eupraxia Pharmaceuticals has 67,268,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 67,268,250
- Owned by Insiders
- 10.01%
- Owned by Institutions
- 32.35%
Financial Efficiency
Eupraxia Pharmaceuticals’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -48.56%.
- Return on Equity (ROE)
- -0.48
- Return on Assets (ROA)
- -0.46
- Return on Invested Capital (ROIC)
- -48.56%
- Return on Capital Employed (ROCE)
- -0.49
- Revenue Per Employee
- 0
- Profits Per Employee
- -801.05K
- Employee Count
- 49
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Eupraxia Pharmaceuticals is -5.89. Eupraxia Pharmaceuticals’s PEG ratio is 0.42.
- PE Ratio
- -5.89
- PS Ratio
- 0.00
- PB Ratio
- 3.44
- Price to FCF
- -9.18
- Price to Operating Cash Flow
- -9.40
- PEG Ratio
- 0.42
Income Statement
In the last 12 months, Eupraxia Pharmaceuticals had revenue of 0 and earned -39.25M in profits. Earnings per share was -1.05.
- Revenue
- 0
- Gross Profit
- -241.88K
- Operating Income
- -39.11M
- Pretax Income
- -39.26M
- Net Income
- -39.25M
- EBITDA
- -38.86M
- Earnings Per Share (EPS)
- -1.05
Cash Flow
In the last 12 months, operating cash flow was -44.04M and capital expenditures -823,769, giving a free cash flow of -44.87M billion.
- Operating Cash Flow
- -44.04M
- Free Cash Flow
- -44.87M
- Free Cash Flow per Share
- -0.66
Dividends & Yields
Eupraxia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10.82%
- Earnings Yield
- -14.14%
Stock Price Statistics
- Beta
- 1.16
- 52-Week Price Change
- -1.56%
- 50-Day Moving Average
- 10.69
- 200-Day Moving Average
- 10.02
- Relative Strength Index (RSI)
- 39.69
- Average Volume (3m)
- 90.49K
Important Dates
Eupraxia Pharmaceuticals upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
Eupraxia Pharmaceuticals as a current ratio of 15.12, with Debt / Equity ratio of 0.19%
- Current Ratio
- 15.12
- Quick Ratio
- 15.12
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.07
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Eupraxia Pharmaceuticals has paid 19.42K in taxes.
- Income Tax
- 19.42K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Eupraxia Pharmaceuticals EV to EBITDA ratio is -5.23, with an EV/FCF ratio of -7.65.
- EV to Sales
- 0.00
- EV to EBITDA
- -5.23
- EV to Free Cash Flow
- -7.65
- EV to Operating Cash Flow
- -7.79
Balance Sheet
Eupraxia Pharmaceuticals has CAD 125.61M in cash and marketable securities with CAD 3.40M in debt, giving a net cash position of CAD 122.21M billion.
- Cash & Marketable Securities
- CAD 125.61M
- Total Debt
- CAD 3.40M
- Net Cash
- CAD 122.21M
- Net Cash Per Share
- CAD 1.82
- Tangible Book Value Per Share
- CAD 1.78
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Eupraxia Pharmaceuticals is CAD 24.68, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- CAD 24.68
- Price Target Upside
- 178.55% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -17.60%
Scores
- Smart Score
- 10
- AI Score
- 44

